CRWV has lost 15% this week and 30% over the past month, arriving at $67.30 with its first post-IPO earnings print just eight days away — and the data tells a story of shorts retreating even as the stock continues to fall.
The most striking development in positioning is the sharp unwinding of short interest. Shares short dropped roughly 30% week-on-week, from nearly 90 million shares to about 64 million, pulling SI % of Free Float from what was running above 20% down to 16.5%. That is still a high absolute level, but the direction is unambiguous — bears who built positions during the July peak are covering into weakness, not pressing it. The lending market is consistent with that read: availability has tightened somewhat, running at 202%, down from above 300% in late June and well below the 574% seen in mid-June when borrowing was plentiful. Cost to borrow remains negligible at 0.45%, down 14% on the week — there is no squeeze dynamic here, just orderly covering. Options positioning is similarly mild. The put/call ratio of 0.81 sits only about 0.7 standard deviations above its 20-day average of 0.78, well within normal range and nowhere near the 52-week defensive extreme of 1.32. Overall, positioning looks cautious but not panicked — shorts are retreating even as the stock drops, which is an unusual combination ahead of a catalyst.
The Street is resetting anchors lower without abandoning the bull thesis. As covered in the prior note last Tuesday, the recent wave of analyst moves was dominated by target-price cuts: Barclays took its target from $120 to $90, Jefferies from $160 to $150, Mizuho to $100, Macquarie to $130. Since then the picture has not materially changed. The consensus sits at Buy, with a mean target near $140 — more than double the current price of $67.30. That gap has widened considerably given the stock's continued slide. The bull case centres on AI infrastructure scarcity and the reported $125bn backlog; the bear case remains the same: extreme leverage, customer concentration around Microsoft, and the execution risk that comes with a company still burning cash. The EV/EBITDA multiple has compressed to 5.2x, with the price-to-book ratio down to 10.7x from above 14x a month ago. The ORTEX factor scores offer a nuanced read — EPS momentum ranks in the 94th percentile over 30 days and 90th over 90 days, reflecting strong forward estimate revisions, but the short score of 62.9 and the 12-month forward EPS growth rank of just 19 suggest the market is not yet rewarding that momentum.
Insider selling adds a layer worth watching. CEO and founder Michael Intrator sold approximately 205,000 shares on July 21 across multiple transactions, netting roughly $14.4m in aggregate — the same day the stock was trading near $76-$80. The 90-day net is modestly positive at around 419,000 shares, suggesting earlier buying offsets some of the recent selling, but the timing of a material CEO sale one week before earnings will attract scrutiny. The co-founders Brian Venturo and Brannin McBee have also reduced their positions in recent filings.
The earnings history available for CRWV is limited but pointed. The May 7 print produced a 17% single-day decline and a 17% five-day loss — a severe reaction for a stock that was already highly valued. The June 8 result was more contained, with a 2% drop on the day followed by a 6% recovery over five days. Two prints, two different outcomes. What the data confirms is that the stock is capable of large moves around results, and with SI still at 16.5% of float even after significant covering, any surprise — in either direction — lands on a substrate of elevated short positioning and a wide gap between price and consensus target.
The August 6 print is the event that resolves much of the current tension: whether the backlog is converting to revenue at the pace the bull case requires, and whether the CEO's pre-earnings stock sales carried a signal worth heeding.
See the live data behind this article on ORTEX.
Open CRWV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
